Actavis PLC (NYSE:ACT)

301.32
Delayed Data
As of Mar 26
 +0.69 / +0.23%
Today’s Change
184.71
Today|||52-Week Range
317.72
+17.06%
Year-to-Date
Leon Cooperman Is Under Investigation and This Is Where He Is Investing His Money
8:24am / TheStreet.com
S&P 500 entry lifts American Airlines
Mar 17 / FT.com
Omega Advisors probed over share trading
Mar 26 / FT.com
Actavis Receives FDA Approval for Saphris' Label Expansion - Analyst Blog
Mar 16 / Zacks.com
Actavis takes 'specialty pharma' route to health
Mar 26 / FT.com
Raised offer from Valeant knocks Endo out of Salix race
Mar 16 / FT.com
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Mar 25 / Zacks.com
ACADIA Down on Nuplazid NDA Delay and CEO Resignation - Analyst Blog
Mar 13 / Zacks.com
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Mar 25 / Zacks.com
Actavis' Generic Pulmicort on Hold until Final Verdict - Analyst Blog
Mar 13 / Zacks.com
Week in Review, March 21
Mar 20 / FT.com
The Zacks Analyst Blog Highlights: NXP Semiconductors, Actavis and Cimpress - Press R...
Mar 13 / Zacks.com
Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celg...
Mar 20 / TheStreet.com
Endo looks to crash Valeant-Salix deal
Mar 11 / FT.com
AstraZeneca Up on Positive Late-Stage Lung Disease Results - Analyst Blog
Mar 19 / Zacks.com
US corporate debt sales top $53bn
Mar 06 / FT.com
Actavis' Depression Drug Gains FDA Approval for New Dose - Analyst Blog
Mar 17 / Zacks.com
AbbVie joins the pharma chain reaction
Mar 05 / FT.com
American Airlines Group (AAL) to Enter Coveted S&P 500 - Analyst Blog
Mar 17 / Zacks.com
Actavis's $21bn bond sale is second-largest on record
Mar 03 / FT.com
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Mar 17 / Zacks.com
11 stocks hedge funds and mutual funds love now
Mar 02 / CNNMoney.com
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Mar 17 / Zacks.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account